Tas-102
Clear Cell Sarcoma of the Kidney
Roswell Park Cancer InstituteunclassifiedPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Clear Cell Sarcoma of the Kidney cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib National Cancer Institute (NCI) | Phase 1/2 | B |
VINCRISTINE SULFATE Children's Oncology Group | Phase 2 | B |
Carboplatin Children's Oncology Group | Phase 2 | B |
Irinotecan Children's Oncology Group | Phase 2 | B |
ETOPOSIDE Children's Oncology Group | Phase 2 | B |
View all 13 →
Same molecule, other indications
Tas-102 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →